- Home
- PED vs AARD Comparison
PED vs AARD Comparison
Compare PED & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PED | AARD |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.8M | 107.7M |
| IPO Year | 2012 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PED | AARD |
|---|---|---|
| Price | $13.34 | $5.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $30.00 | $15.29 |
| AVG Volume (30 Days) | 27.7K | ★ 134.1K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $45,751,000.00 | N/A |
| Revenue This Year | $171.75 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.67 | N/A |
| 52 Week Low | $0.43 | $3.35 |
| 52 Week High | $18.89 | $17.94 |
Technical Indicators
Market Signals| Indicator | PED | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 54.12 | 44.85 |
| Support Level | $14.12 | $4.91 |
| Resistance Level | $16.70 | $6.01 |
| Average True Range (ATR) | 1.08 | 0.59 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 27.86 | 47.51 |
Price Performance
Historical ComparisonAbout PED Pedevco Corp.
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties with a long production history, well-defined geology, and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming, the Powder River Basin (PRB) in Wyoming, and the San Andres formation of the Permian Basin situated in West Texas and eastern New Mexico (the Permian Basin).
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.